[go: up one dir, main page]

WO1999061071A3 - Techniques permettant de marquer des vecteurs a base d'acides nucleiques avec des oligonucleotides formant des triplex et d'analyser la distribution desdits vecteurs - Google Patents

Techniques permettant de marquer des vecteurs a base d'acides nucleiques avec des oligonucleotides formant des triplex et d'analyser la distribution desdits vecteurs Download PDF

Info

Publication number
WO1999061071A3
WO1999061071A3 PCT/US1999/011511 US9911511W WO9961071A3 WO 1999061071 A3 WO1999061071 A3 WO 1999061071A3 US 9911511 W US9911511 W US 9911511W WO 9961071 A3 WO9961071 A3 WO 9961071A3
Authority
WO
WIPO (PCT)
Prior art keywords
labeled
nucleic acid
imaging
tfos
triplex
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1999/011511
Other languages
English (en)
Other versions
WO1999061071A2 (fr
Inventor
Igor G Panyutin
Ronald D Neumann
Andrew N Luu
Olga A Sedelnikova
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Original Assignee
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Health and Human Services filed Critical US Department of Health and Human Services
Priority to AU43124/99A priority Critical patent/AU4312499A/en
Publication of WO1999061071A2 publication Critical patent/WO1999061071A2/fr
Publication of WO1999061071A3 publication Critical patent/WO1999061071A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0491—Sugars, nucleosides, nucleotides, oligonucleotides, nucleic acids, e.g. DNA, RNA, nucleic acid aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6839—Triple helix formation or other higher order conformations in hybridisation assays

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Optics & Photonics (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)

Abstract

Des oligonucléotides formant des triplex (TFO) peuvent former in vitro, avec des séquences nucléotidiques cibles contenues dans un acide nucléique, des complexes de triplex qui, après introduction dans des cellules eucaryotes en culture, restent stables à l'intérieur de celles-ci au moins 48 heures. La stabilité de ces complexes de triplex formés par liaison de TFO marqués à l'iode 125 à un acide nucléique cible peut être contrôlée quantitativement par radio-impression. Le nombre de cassures de brins d'ADN provoquées par l'iode 125 introduit dans l'acide nucléique cible est déterminé. Ce nombre est proportionnel au nombre de complexes de triplex présents dans l'acide nucléique. Selon l'invention, les TFO sont marqués in vitro au moyen d'agents d'imagerie pouvant être détectés in vivo par des techniques d'imagerie telles que l'imagerie à gamma-caméra, le scanner à balayage rectiligne, l'IRM, la tomographie à émission de positrons (PET) et la tomographie d'émission monophotonique (SPECT). On laisse les TFO marqués se lier à leur acide nucléique cible et former avec lui des complexes de triplex, puis on administre à un organisme pluricellulaire une composition pharmaceutique renfermant les triplex marqués. On utilise ensuite les techniques d'imagerie capables de détecter l'acide nucléique marqué afin de contrôler de manière non invasive la biodistribution de l'acide nucléique dans l'organisme du patient. L'invention constitue ainsi un nouvel outil important pour développer les techniques d'apport d'acides nucléiques faisant partie de protocoles de thérapie génique.
PCT/US1999/011511 1998-05-26 1999-05-26 Techniques permettant de marquer des vecteurs a base d'acides nucleiques avec des oligonucleotides formant des triplex et d'analyser la distribution desdits vecteurs Ceased WO1999061071A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU43124/99A AU4312499A (en) 1998-05-26 1999-05-26 Methods for labeling nucleic acid vectors with triplex-forming oligonucleotides and monitoring vector distribution in vivo

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8670498P 1998-05-26 1998-05-26
US60/086,704 1998-05-26

Publications (2)

Publication Number Publication Date
WO1999061071A2 WO1999061071A2 (fr) 1999-12-02
WO1999061071A3 true WO1999061071A3 (fr) 2000-06-22

Family

ID=22200322

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/011511 Ceased WO1999061071A2 (fr) 1998-05-26 1999-05-26 Techniques permettant de marquer des vecteurs a base d'acides nucleiques avec des oligonucleotides formant des triplex et d'analyser la distribution desdits vecteurs

Country Status (2)

Country Link
AU (1) AU4312499A (fr)
WO (1) WO1999061071A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1319710A4 (fr) * 2000-09-19 2005-02-09 Takara Bio Inc Procede de formation de complexes
MX2020013183A (es) 2018-06-07 2021-04-13 Amgen Inc Ensayo de deteccion de conjugados de proteina-polinucleotido.

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992011390A1 (fr) * 1990-12-17 1992-07-09 Idexx Laboratories, Inc. Detection de sequences d'acide nucleique par la formation d'une triple helice de l'adn
US5789155A (en) * 1987-10-30 1998-08-04 California Institute Of Technology Process for identifying nucleic acids and triple helices formed thereby
WO1998037231A2 (fr) * 1997-02-22 1998-08-27 Ruprecht-Karls-Universität Heidelberg Marquage d'acides nucleiques avec des melanges de sondes speciales
WO1999024622A1 (fr) * 1997-11-10 1999-05-20 Princeton University Hybridation in-situ triplex

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5789155A (en) * 1987-10-30 1998-08-04 California Institute Of Technology Process for identifying nucleic acids and triple helices formed thereby
WO1992011390A1 (fr) * 1990-12-17 1992-07-09 Idexx Laboratories, Inc. Detection de sequences d'acide nucleique par la formation d'une triple helice de l'adn
WO1998037231A2 (fr) * 1997-02-22 1998-08-27 Ruprecht-Karls-Universität Heidelberg Marquage d'acides nucleiques avec des melanges de sondes speciales
WO1999024622A1 (fr) * 1997-11-10 1999-05-20 Princeton University Hybridation in-situ triplex

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
DEBIN A ET AL: "Investigation of the formation and intracellular stability of purine.(purine/pyrimidine) triplexes.", NUCLEIC ACIDS RESEARCH, (1997 MAY 15) 25 (10) 1965-74., XP002121050 *
DEWANJEE M. K. ET AL.: "Noninvasive Imaging of c-myc Oncogene Messeger RNA with Indium-111-Antisense Probes in a Mammary Tumor-Bearing Mouse Model", THE JOURNAL OF NUCLEAR MEDICINE, vol. 35, no. 6, 1994, pages 1054 - 1063, XP002121053 *
EBBINGHAUS S W ET AL: "EFFICIENT DELIVERY OF TRIPLEX FORMING OLIGONUCLEOTIDES TO TUMOR CELLS BY ADENOVIRUS-POLYLYSINE COMPLEXES", GENE THERAPY, vol. 3, no. 4, 1 April 1996 (1996-04-01), pages 287 - 297, XP000600781 *
PANUTYN I. G. ET AL.: "Radioprobing of DNA: distribution of DNA breaks produced by decay of 125-I incorporated into a triplex-forming oligonucleotide correlates with geometry of the triplex.", NUCLEIC ACID RESEARCH, vol. 25, no. 4, 1997, pages 883- - 887, XP002121051 *
PANYUTIN I. G. ET AL.: "Sequence specific DNA double-strand breaks induced by triplex forming I labeled oligonucleotides", NUCLEIC ACID RESEARCH, vol. 22, no. 23, 1994, pages 4979 - 4982, XP002121052 *
SEDELNIKOVA O.A. ET AL: "The stability of DNA triplexes inside cells as studied by iodine-125 radioprinting.", NUCLEIC ACIDS RESEARCH, (1 OCT 1999) 27/19 (3844-3850)., XP002121049 *

Also Published As

Publication number Publication date
AU4312499A (en) 1999-12-13
WO1999061071A2 (fr) 1999-12-02

Similar Documents

Publication Publication Date Title
Louie et al. In vivo visualization of gene expression using magnetic resonance imaging
Gambhir et al. Imaging gene expression: principles and assays
Acton et al. Imaging reporter genes for cell tracking with PET and SPECT
Contag et al. Use of reporter genes for optical measurements of neoplastic disease in vivo
Wang et al. Recent progress in metal-organic cages for biomedical application: Highlighted research during 2018–2023
KR102026096B1 (ko) 핵산 검출용 형광핵산나노구조체-그래핀 바이오센서
Keliris et al. A smart 19F and 1H MRI probe with self‐immolative linker as a versatile tool for detection of enzymes
AU2001249297A1 (en) Whole-body optical imaging of gene expression and uses thereof
WO2001071009A2 (fr) Imagerie optique corps entier de l'expression genique et utilisations correspondantes
WO2018226575A1 (fr) Imagerie et détection à base de ribonucléoprotéine
CN105734159B (zh) 食管鳞癌的分子标记物
Lee et al. Magnetic resonance reporter gene imaging
Fukaya Dynamic regulation of anterior-posterior patterning genes in living Drosophila embryos
Piwnica‐Worms et al. Technoreview: Molecular imaging of host–pathogen interactions in intact small animals
Chakrabarti et al. Radiohybridization PET imaging of KRAS G12D mRNA expression in human pancreas cancer xenografts with [64Cu] DO3A-peptide nucleic acid-peptide nanoparticles
Ross et al. Magnetic resonance imaging in cancer research
Song et al. Genetically encoded reporter genes for microRNA imaging in living cells and animals
Bhaumik et al. Molecular imaging of gene expression in living subjects by spliceosome-mediated RNA trans-splicing
Qiao et al. Death and proliferation time course of stem cells transplanted in the myocardium
WO1999061071A3 (fr) Techniques permettant de marquer des vecteurs a base d'acides nucleiques avec des oligonucleotides formant des triplex et d'analyser la distribution desdits vecteurs
Lee et al. L-DNA linear duplex: An efficient drug delivery carrier with a simple structure
Gambhir Quantitative assay development for PET
Hauck et al. Whole animal in vivo imaging after transient, nonviral gene delivery to the rat central nervous system
US8236572B2 (en) Chemical exchange saturation transfer based MRI using reporter genes and MRI methods related thereto
Chien et al. Using [18F] FBAU for imaging brain tumor progression in an F98/tk-luc glioma-bearing rat model

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

NENP Non-entry into the national phase

Ref country code: KR

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase